Search
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.
Nabumetone
go.drugbank.com/drugs/DB00461Approved[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. … [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.
Mixtures: NuDroxiPAK N-500Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigationalThe vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.
Bifidobacterium longum infantis
go.drugbank.com/drugs/DB14222ApprovedInvestigationalWithdrawnMixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADETBordetella pertussis toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14388ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer FertigspritzeBempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Apomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigational[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders. … Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.
Categories: Drugs Used in Erectile DysfunctionProducts: APO-GO PEN 10 MG/ML, Apo-go Pen 10 mg/ml - InjektionslösungSotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigationalSotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992. … in atrial fibrillation or flutter.
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexInternational brands: Xi An LinForeskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedTo construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. … The keratinocytes form a stratified epithelium, with growing basal cells at the innermost layer and the keratinized, and mostly impermeable outer stratum corneum layer on the surface [L2452].